FcResolv NOG Mouse Model

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • 19164-F
    ko/ko;ko/ko;sp/sp;ko/ko
    NOD.Cg-Fcgr2btm1Ttk Fcer1gtm1Rav Prkdcscid Il2rgtm1Sug
  • 19164-M
    ko/ko;ko/ko;sp/sp;ko/y
    NOD.Cg-Fcgr2btm1Ttk Fcer1gtm1Rav Prkdcscid Il2rgtm1Sug
  • The FcResolv NOG is a super immunodeficient NOG mouse that has a further reduction in residual murine immune activity via ablation of mouse Fc gamma receptors (FcγRs) to improve accuracy of results.
  • Murine FcγRs can confound experiments in several ways, leading to false positive or negative results. Removing murine FcγRs provides improved accuracy for efficacy assessment of antibody-based therapies which include an Fc domain.
  • Lacks all murine Fcγ receptors, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.
  • Can be used in a similar fashion to the NOG mouse, including for xenograft and immune system humanization experiments.
  • FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse; human cell frequencies may vary somewhat between the two humanized models.

NOG Characteristics

  • Amenable to immune system humanization via engraftment of human hematopoietic stem cells (HSCs).
  • Immunodeficient model lacking mature T, B, and NK cells, with reduced complement activity and dysfunctional macrophages and dendritic cells.
  • Excellent model for a variety of xenograft and human cell engraftment studies.
  • Applications in research involving cancer, infectious disease, immunology, regenerative medicine, humanization, autoimmune disease, immunotherapy, vaccine, GvHD/transplantation, hematopoiesis, inflammation/allergy, and safety assessment.
  • The Il2rg gene is sex-linked.

Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The FcResolv NOG mouse was developed by Takeshi Takahashi of the Central Institute for Experimental Animals (CIEA) in Japan. The Fcer1gtm1Rav mutation was developed in the laboratory of J.V. Ravetch, Sloan-Kettering Institute. The Fcgr2btm1Ttk mutation was developed in the laboratory of T. Takai of Okayama University. These two mutations were backcrossed onto the CIEA NOG mouse®. Taconic received stock in 2021, and the line was derived through embryo transfer. The mice are maintained by breeding females homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid and Il2rgtm1Sug mutant alleles with males that are homozygous for the Fcer1gtm1Rav, Fcgr2btm1Ttk, Prkdcscid alleles and hemizygous for the Il2rgtm1Sug mutant allele.

Availability:

Available now*

*Please note that advanced order placement is encouraged for male mice. Ordering 4 or more weeks prior to the desired shipping date is recommended when requesting males older than 3-weeks of age.

Color:

Albino

Species:

Mouse

Initial Publication:

  • Katano I, Ito R, Kawai K, Takahashi T. Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse. Front Immunol. 2020 Oct 7;11:532684.
  • Katano I, Hanazawa A, Otsuka I, Yamaguchi T, Mochizuki M, Kawai K, Ito R, Goto M, Kagawa T, Takahashi T. Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Sci Rep. 2021 Oct 26;11(1):21087.


Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758

FcResolv NOG PERMITS ACCURATE DETECTION OF ANTIBODY-BASED IMMUNOTHERAPY EFFICACY

Ablating murine FcgR activity enables accurate detection of immunotherapy efficacy in humanized mice engrafted with tumors. Nivolumab (anti-PD1) does not suppress tumor growth in HSC-engrafted NOG mice (bottom row) but displays anti-tumor efficacy in HSC-engrafted FcResolv NOG mice (top row).
Figure 1: Ablating murine FcγR activity enables accurate detection of immunotherapy efficacy in humanized mice engrafted with tumors. Nivolumab (anti-PD1) does not suppress tumor growth in HSC-engrafted NOG mice (bottom row) but displays anti-tumor efficacy in HSC-engrafted FcResolv NOG mice (top row). From Katano et al. 2021.

HSC-ENGRAFTED BRANDNAME NOG SUPPORTS HIGHER LEVELS OF HUMAN CELLS COMPARED TO NOG

FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse.
Figure 2: FcResolv NOG mice support higher average levels of human cells following engraftment with HSCs compared to the base NOG mouse. From Katano et al. 2021.
Close

Welcome! Tell us a little about yourself